



# Treatment Selection in Advanced HCC

First Line	Second Line	Third Line
Sorafenib	Cabozantinib <sup>a</sup>	Cabozantinib <sup>a</sup>
Lenvatinib	AFP $\geq$ 400 ng/mL: Ramucirumab	Nivolumab or Pembrolizumab <sup>a</sup>
	Regorafenib <sup>a</sup>	

<sup>a</sup>Not FDA approved.

## References

1. EASL. *J Hepatol*. 2018;69:182-236.
2. [ClinicalTrials.gov](https://clinicaltrials.gov/ct2/show/study/NCT02576509) . NLM Identifier: NCT02576509.
3. NCCN. Hepatobiliary cancers. V3.2019.
4. Bristol-Myers Squibb. Press release. June 24, 2019.